» Articles » PMID: 38001621

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Nov 25
PMID 38001621
Authors
Affiliations
Soon will be listed here.
Abstract

Quantitative PCR for specific mutation is being increasingly used in Acute Myeloid Leukemia (AML) to assess Measurable Residual Disease (MRD), allowing for more tailored clinical decisions. To date, standardized molecular MRD is limited to typical NPM1 mutations and core binding factor translocations, with clear prognostic and clinical implications. The monitoring of other identified mutations lacks standardization, limiting its use and incorporation in clinical trials. To overcome this problem, we designed a plasmid bearing both the sequence of the mutation of interest and the ABL reference gene. This allows the use of commercial standards for ABL to determine the MRD response in copy number. We provide technical aspects of this approach as well as our experience with 19 patients with atypical NPM1, RUNX1 and IDH1/2 mutations. In all cases, we demonstrate a correlation between response and copy number. We further demonstrate how copy number monitoring can modulate the clinical management. Taken together, we provide proof of concept of a novel yet simple tool, which allows in-house MRD monitoring for identified mutations, with ABL-based commercial standards. This approach would facilitate large multi-center studies assessing the clinical relevance of selected MRD monitoring.

Citing Articles

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Frisch A, Ganzel C, Ofran Y, Krayem B, Haran A, Vainstein V Eur J Haematol. 2024; 114(4):641-649.

PMID: 39740005 PMC: 11880982. DOI: 10.1111/ejh.14375.

References
1.
Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A . Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016; 374(5):422-33. DOI: 10.1056/NEJMoa1507471. View

2.
Tiong I, Loo S . Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. Int J Mol Sci. 2023; 24(5). PMC: 10003715. DOI: 10.3390/ijms24054790. View

3.
Lowenberg B, Pabst T, Maertens J, Gradowska P, Biemond B, Spertini O . Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021; 5(4):1110-1121. PMC: 7903238. DOI: 10.1182/bloodadvances.2020003855. View

4.
Della Starza I, De Novi L, Elia L, Bellomarino V, Beldinanzi M, Soscia R . Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Cancers (Basel). 2023; 15(2). PMC: 9856386. DOI: 10.3390/cancers15020374. View

5.
Rothenberg-Thurley M, Amler S, Goerlich D, Kohnke T, Konstandin N, Schneider S . Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018; 32(7):1598-1608. PMC: 6035153. DOI: 10.1038/s41375-018-0034-z. View